Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 5Carcinoma, Ovarian Epithelial 4Peritoneal Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma 2Neoplasms, Glandular and Epithelial 1Neoplasms 1EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1Ascites 1Adenocarcinoma 1

Interventions

anlotinib 2Ocoxin 2Bevacizumab 2pembrolizumab 1olaparib 1niraparib 1lenvatinib 1catumaxomab 1Papanicolaou Test 1Paclitaxel 1Human Papillomavirus DNA Tests 1Filgrastim 1Drug Therapy 1Colposcopy 1Cell Count 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × catumaxomab × Gynecologic × Clear all
NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Neovii Biotech

Phase 2 Completed
32 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡